High Lipoprotein (a) Concentration Is Associated with Diabetic Nephrophaty
Meutia Atika Faradilla,
Karina Shasri Anastasya,
Yohana,
Meiyanti,
Andira Larasari,
Daniella Satyasari,
Endrico Xavierees Tungka
Issue:
Volume 8, Issue 3, September 2023
Pages:
37-41
Received:
6 August 2023
Accepted:
4 September 2023
Published:
13 September 2023
Abstract: Aims: Lipoprotein (a) [Lp(a)] has been well recognized as a risk factor for both micro and macrovascular complications in diabetes, due to its atherogenic effects. Studies suggested that serum lipoprotein (a) [Lp(a)] concentration may take part in the aggravation of diabetic nephropathy. Accumulating evidence suggests that higher serum Lp(a) may be associated with impaired renal function in populations. Therefore this study comprehensively evaluates the association between Lipoprotein (a) and diabetic nephropathy in patients with type 2 diabetes mellitus. Methods: One hundred subjects (50 with diabetic nephrophaty and 50 type 2 diabetes mellitus without nephrophaty) were studied. The examination used blood serum where lipoprotein a used the ELISA method. Nonpara- metric Mann–Whitney U-tests were used to compare the levels of lipoprotein a in diabetic nephrophaty and Type 2 DM without diabetic nephropathy. Results: Lipoprotein a in the diabetic nephropathy group was higher when compared to the type 2 DM group without nephropathy (OR = 2.8; 95%; CI = 1.84-12.07). Conclution: High lipoprotein (a) concentration are associated with diabetic nephrophaty. Lipoprotein may reflect chronic underlying pathophysiological processes involved in development of complications of T2DM and serum Lp(a) can be considered as a promising predictive factor for the diagnosis of earlier diabetic nephropathy.
Abstract: Aims: Lipoprotein (a) [Lp(a)] has been well recognized as a risk factor for both micro and macrovascular complications in diabetes, due to its atherogenic effects. Studies suggested that serum lipoprotein (a) [Lp(a)] concentration may take part in the aggravation of diabetic nephropathy. Accumulating evidence suggests that higher serum Lp(a) may be...
Show More
Michigan Neurologic Scale in Early Screening for Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus
Issue:
Volume 8, Issue 3, September 2023
Pages:
42-44
Received:
1 September 2023
Accepted:
13 September 2023
Published:
25 September 2023
Abstract: Objective: To apply the Michigan Neuropathy Screening Scale in social health to achieve early detection, intervention, and treatment of diabetic neuropathy in patients with type 2 diabetes mellitus. Methods: Fifty-eight patients with type 2 diabetes mellitus with weakened dorsalis pedis arteries attending the outpatient clinic of Huangtian Community Health Service Center, Bao'an District Central Hospital, Shenzhen City, China, from April to June 2023 were selected to undergo the early screening of diabetic neuropathy through MNSI, and those with abnormal results were pulled into the unified management of the micro-credit group for regular popularization of science. Before and after the management, the patients were surveyed on their understanding of diabetic neuropathy-related contents and their satisfaction with the doctors, and t-tests were performed on the two results. Results: A total of 54 valid questionnaires were obtained, of which 14 had abnormal questionnaire results, and 5 were diagnosed with diabetic neuropathy after the abnormal ones went to the hospital for electromyography. Patients' scores on the survey of understanding of diabetic neuropathy were significantly higher after management than before management (P<0.05), and their satisfaction with their doctors improved (P<0.05). The regular popularization of the WeChat group allowed patients to have a correct knowledge of diabetic neuropathy, increased attention and reduced panic, and more trust and confidence in our doctors, thus increasing the contracting rate and consultation rate of family doctors in key populations. Conclusion: MNSI is effective and convenient for early detection, intervention and treatment of diabetic neuropathy, and is worth promoting its application in social welfare.
Abstract: Objective: To apply the Michigan Neuropathy Screening Scale in social health to achieve early detection, intervention, and treatment of diabetic neuropathy in patients with type 2 diabetes mellitus. Methods: Fifty-eight patients with type 2 diabetes mellitus with weakened dorsalis pedis arteries attending the outpatient clinic of Huangtian Communit...
Show More
